Inhaled GM-CSF shows promise in providing a less invasive option for autoimmune PAP management and offers a potential treatment alternative in locations where equipment for whole-lung lavage is lacking. This evidence concerns the gene CSF2 and autoimmune pulmonary alveolar proteinosis.